肿瘤细胞治疗研究
英文原题：Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm.
母细胞性浆细胞样树突状细胞肿瘤（BPDCN）是一种罕见且侵袭性的血液系统恶性肿瘤，其特征是 CD123 和 CD303 表面抗原的过表达。
母细胞性浆细胞样树突细胞肿瘤（BPDCN）是一种罕见且侵袭性的血液系统恶性肿瘤，特征为 CD123 和 CD303 表面抗原过表达。这些分子标志物对于疾病诊断和靶向治疗开发至关重要。传统 BPDCN 治疗方案疗效有限，凸显开发新型创新治疗策略的必要性。免疫治疗的近期进展，尤其是治疗性单克隆抗体、双特异性 T 细胞衔接器和 CAR-T 细胞疗法，提供了有前景的替代选择。首个获 FDA 批准的 CD123 靶向疗法 tagraxofusp 显著改善患者结局。此外，新兴的 CD303 靶向策略也有望进一步推动治疗进展。尽管取得这些突破，治疗耐药和毒性等挑战仍然存在。本综述介绍 BPDCN 治疗最新进展，强调 CD123 和 CD303 作为精准医学干预靶点的潜力。靶向免疫疗法持续演进，有望改善患者生存并重新定义血液系统恶性肿瘤治疗范式。
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens. These molecular markers play a crucial role in diagnosing diseases and developing targeted therapies. Traditional treatment options for BPDCN have demonstrated limited effectiveness, highlighting the need for new and innovative therapeutic strategies. Recent advances in immunotherapy, particularly therapeutic monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapy, have provided promising alternatives. Tagraxofusp, the first FDA-approved CD123-targeted therapy, has significantly improved patient outcomes. Additionally, emerging CD303-targeting strategies offer the potential for further advancements. Despite these breakthroughs, challenges such as treatment resistance and toxicity remain. This review explores the latest developments in BPDCN treatment, emphasizing the potential of CD123 and CD303 as targets for precision medicine interventions. The ongoing evolution of targeted immunotherapies holds promise for improving patient survival and redefining treatment paradigms in hematologic malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
